Published in Gene Therapy Weekly, May 22nd, 1995
The study is designed to demonstrate that the ability of CellPro's Ceprate SC Stem Cell Concentration System to positively select CD34 antigen-expressing stem cells from peripheral blood also results in a significant depletion of tumor cells from the resulting stem cell transplant.
The principal investigator for the study is Peter A. McSweeney, M.D., associate in clinical research at the Hutchinson Center. Primary objectives of the 15-patient pilot trial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.